ClinicalTrials.gg
RecruitingNCT06707103TRIVIAUpdated Apr 2, 2025

Tissue Repair Gel in Venous Leg Ulcers in AU/US

A Phase 3 interventional study of TR987 0.1% gel + Standard of Care and Standard of care in Venous Leg Ulcer, Venous Ulcer and Venous Stasis Ulcer, sponsored by TR Therapeutics. Recruiting at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-02.

Sponsored by TR Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn if TR987 0.1% gel + Standard of Care works better than Standard of Care alone to treat Venous Leg Ulcers (VLUs). It will also provide additional information about the safety of drug TR987 0.1% gel.

Read the detailed description

This is an outpatient, randomized, parallel- group, double-blind, multicenter, 16-week study with 2 treatment arms: TR987 0.1% gel + Standard of Care and Standard of Care alone in participants who have a non-healing Venous Leg Ulcer (VLU).

The primary objective is to assess the proportion of participants with Complete Closure of the target ulcer at or before the Week-16 end of treatment (EOT) visit.

Secondary endpoints include:

  • Proportion of participants with Complete Closure of the target ulcer at or before the Week 16 visit AND for whom the ulcer remains closed at the 3-Month Follow-Up visit after such closure (a composite endpoint).
  • Change from baseline in participant's perception of pain level at 12 weeks.
  • Percent change from baseline in the target ulcer area at 12 and 16 weeks. In the event of Complete Closure before these time points, the target ulcer area will be deemed to be zero at those time points for purposes of calculation of this endpoint.
  • Proportion of participants with Complete Closure of the target ulcer at or before the Week 12 treatment visit.
  • Proportion of participants with any significant reduction in pain at or before 12 weeks.

There are also some supplementary and safety endpoints.

02

Conditions studied

  • Venous Leg Ulcer
  • Venous Ulcer
  • Venous Stasis Ulcer
  • Venous Stasis
  • Wound Heal
  • Wound
  • Venous Insufficiency of Leg
  • Non-healing Wound

Keywords

  • Tissue Repair
  • Glucoprime
  • TR Therapeutics
  • Debridement
  • VLU
03

In context

Varicose Ulcer

370 studies on the registry are indexed under Varicose Ulcer; 74 are open to participants now.

This study's planned enrollment of 312 is above the median of 60 across 309 interventional studies indexed under Varicose Ulcer.

Browse Varicose Ulcer studies →

Lead sponsor

TR Therapeutics is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18 years and older
  • Venous insufficiency has been clinically diagnosed clinically and medically confirmed.
  • Females who are neither pregnant nor breastfeeding and if of are on an acceptable method of .
  • The Venous Ulcer should be between 2 cm2 and 12 cm2 at randomization.
  • Target ulcer age must be ≥ 4 weeks at Screening.
  • Participants must have adequate arterial flow as confirmed by ABI/TBI, TB, SPP, TCPo2, or Duplex Doppler.
  • (BMI) ≤ 50 kg/m2.
  • ≤12%.

Exclusion criteria

Exclusion Criteria:

  • Target ulcer has been treated with prohibited medications or therapies.
  • History of radiation at the target ulcer site.
  • Target ulcer decreases in area by 30% or more during screening period.
  • History of osteomyelitis at the target ulcer within 6 months of screening.
  • History of cancer in the preceding 5 years (except as noted in the protocol).
  • Participants considered nutritionally deficient.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
312 participants (estimated)

Study arms

  • Experimental
    TR987 0.1% gel + Standard of Care

    Participants will receive up to 16 weeks of TR987 0.1% gel topically + Standard of Care (wound cleansing/dressings and compression bandaging). Treatment will be twice weekly for the first four weeks then weekly for the remaining 12 weeks.

    Drug: TR987 0.1% gel + Standard of Care

  • Other
    Standard of Care

    Participants will receive Standard of Care (wound cleansing/dressings and compression bandaging). Treatment will be twice weekly for the first four weeks then weekly for the remaining 12 weeks.

    Other: Standard of care

Interventions

  • DrugTR987 0.1% gel + Standard of Care

    6mg topical gel for application plus Standard of Care (wound cleansing/dressings and compression bandaging)

    Also known as: Glucoprime

  • OtherStandard of care

    Standard of Care (wound cleansing/dressings and compression bandaging)

06

What researchers measure

Primary outcomes

  1. Proportion of participants with Complete Closure of the target ulcer at or before the Week-16 end of treatment (EOT) visit.

    Patient count

    Time frame: 16 weeks

Secondary outcomes

  1. Proportion of participants with Complete Closure of the target ulcer at or before the Week 16 visit AND for whom the ulcer remains closed at the 3-Month Follow-Up visit after such closure (a composite endpoint).

    Patient count

    Time frame: 16 weeks

  2. Change from baseline in participant's perception of pain level at 12 weeks.

    Pain to be measured on a 10 point numeric rating scale

    Time frame: 12 weeks

  3. Percent change from baseline in the target ulcer area at 12 and 16 weeks. In the event of Complete Closure before these time points, the target ulcer area will be deemed to be zero at those time points for purposes of calculation of this endpoint.

    Measure the are of the wound in cm2 at baseline and at 12 and 16 weeks and calculate the percentage change

    Time frame: 12 and 16 weeks

  4. Proportion of participants with Complete Closure of the target ulcer at or before the Week 12 treatment visit.

    Count the number of patients with complete closure and divide by the total number of patients

    Time frame: 12 weeks

  5. Proportion of participants with any significant reduction in pain at or before 12 weeks.

    Count the number of patients with any significant reduction in pain and divide by the total number of patients

    Time frame: 12 weeks

07

Study locations

5 of 12 sites recruiting
  • Clincial Research Site 92
    Jacksonville, Florida 32256, United States
    Recruiting
  • Clincial Research Site 77
    Clinton Twp, Michigan 48038, United States
    Recruiting
  • Clincial Research Site 82
    Lake Success, New York 11042, United States
    Not yet recruiting
  • Clinical Research Site 76
    Fort Worth, Texas 76104, United States
    Recruiting
  • Clincial Research Site 62
    Camperdown, New South Wales 2050, Australia
    Not yet recruiting
  • Clinical Research Site 84
    Kogarah, New South Wales 2217, Australia
    Not yet recruiting
  • Clincial Research Site 78
    Orange, New South Wales 2800, Australia
    Not yet recruiting
  • Clincial Research Site 85
    Sydney, New South Wales 2065, Australia
    Not yet recruiting
  • Clincial Research Site 74
    Bendigo, Victoria 3550, Australia
    Not yet recruiting
  • Clincial Research Site 60
    Ivanhoe, Victoria 3079, Australia
    Recruiting
  • Clincial Research Site 65
    Shepparton, Victoria 3630, Australia
    Recruiting
  • Clincial Research Site 75
    Nedlands, Western Australia 6009, Australia
    Not yet recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No — If clinical trial data will be published, this relevant information may be available.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2025; primary completion for Dec 2026, 20 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2024
First posted
Nov 27, 2024
StartEst.
Apr 2025
Primary completionEst.
Dec 2026
CompletionEst.
Feb 2027
Last update
Apr 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06707103
Lead sponsor
TR Therapeutics
Responsible party
Sponsor
First posted
Nov 27, 2024
Start date
Apr 2025 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
Apr 2, 2025

Study contacts

Anhthu Nguyen Vice President, Global Clinical Operations
Contact
anhthu.nguyen@trtherapeutics.com
(+61) 280 034 554

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion